Please assess the completion status of the following clinical trial:

Trial Title: Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed single, primary bronchogenic non-small cell lung cancer meeting the following subtypes:~  * Adenocarcinoma (no bronchioalveolar cell histology)~ * Squamous cell carcinoma~ * Large cell carcinoma~* Meeting the following staging criteria:~  * Stage IIB (T2, N1, M0, or T3, N0, M0)~ * Stage IIIA (T1-3, N2, M0 or T3, N1, M0)~ * Stage IIIB (Any T, N3, M0 or T4, Any N, M0)~* No more than 1 parenchymal lesion in the same lung or in both lungs~* No tumor involving the superior sulcus (e.g., Pancoast tumor)~* Patients must undergo evaluation by the involved thoracic surgeon, medical oncologist, and radiation oncologist prior to registration~* No evidence of metastatic disease~  * Biopsy or aspiration cytology required to confirm the benign diagnosis of CT or MRI abnormalities that potentially represent metastatic disease~ * Biopsy required if all noninvasive tests are indeterminant~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Absolute granulocyte count ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Bilirubin ≤ 3 times upper limit of normal (ULN)~* SGOT and SGPT ≤ 3 times ULN~* Creatinine clearance \> 50 mL/min~* No prior malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or any other cancer from which the patient has been disease-free for 5 years~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective protection~* No significant hearing loss or patient unwilling to accept potential for further hearing loss~* No uncontrolled medical illness by appropriate medical therapy (e.g., myocardial infarction within the past 3 months or liver cirrhosis)~* No symptomatic peripheral neuropathy affecting activities of daily living~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy for lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Cisplatin (Type: EXPERIMENTAL): Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).